Discover how your diet can improve vision health with essential nutrients, carotenoids, and food pairings for long-term eye ...

D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular ...

Some megatrends in health care are occurring that deserve our attention. We already know that as much as one-third of the U.S ...

The adenine base editor corrected the most common mutation associated with Stargardt disease in the ABCA4 gene with no off-target effects.

For the past several years, the halls of the Las Vegas Convention Center have been lousy with AR/VR/XR smart glasses. While ...

Researchers have developed a therapy to treat Stargardt disease, the most common form of inherited macular degeneration, ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

City Therapeutics has inked a new deal with Bausch + Lomb for a gene silencing approach to the eye disorder geographic ...

SolidddVision smartglasses, which correct vision for people living with vision loss due to macular degeneration, will debut at CES.

Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose ...

Under the terms of the option agreement, which was signed in December 2024, Bausch + Lomb has secured the exclusive option to acquire InflammX Therapeutics during an agreed-upon option period based on ...